View in EDS

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

Saved in:
Bibliographic Details
Title: A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Authors: Bender, David1 david-bender@uiowa.edu, Sill, Michael W.2 msill@gogstats.org, Lankes, Heather A.2 hlankes@gogstats.org, Reyes, Henry D.1 henry-reyes@uiowa.edu, Darus, Christopher J.3 cdarus@gmail.com, Delmore, James E.4 james.delmore@awhobgyn.com, Rotmensch, Jacob5 jacob_rotmensch@rush.edu, Gray, Heidi J.6 hgray@u.washington.edu, Mannel, Robert S.7 robert-mannel@ouhsc.edu, Schilder, Jeanne M.8 jschilde@iupui.edu, Hunter, Mark I.9 hunterm@health.missouri.edu, McCourt, Carolyn K.10 McCourtc@wudosis.wustl.edu, Samuelson, Megan I.1, Leslie, Kimberly K.1 Kimberly-leslie@uiowa.edu
Source: Gynecologic Oncology. Sep2015, Vol. 138 Issue 3, p507-512. 6p.
Database: Academic Search Ultimate
Description
ISSN:00908258
DOI:10.1016/j.ygyno.2015.07.018